Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

viral therapies

This page shows the latest viral therapies news and features for those working in and with pharma, biotech and healthcare.

Gilead’s latest Biktarvy data offers hope to HIV patients

Gilead’s latest Biktarvy data offers hope to HIV patients

At week 240, over 99% of participants in both Study 1489 and Study 1490 achieved viral suppression. ... Moreover, at every visit through 240 weeks, the study demonstrated that following the switch to Biktarvy, efficacy was > 96%, demonstrating that

Latest news

  • Gilead set to acquire hepatitis specialist MYR for €1.15bn Gilead set to acquire hepatitis specialist MYR for €1.15bn

    HDV is a severe form of viral hepatitis that carries mortality rates as high as 50% within five years in cirrhotic patients. ... This will build on the work that Gilead has been doing for almost two decades to innovate and improve therapies for viral

  • Roche to collaborate with Dyno on gene therapies for CNS/liver diseases Roche to collaborate with Dyno on gene therapies for CNS/liver diseases

    Dyno will use its CapsidMap platform to develop novel AAV vectors for improved gene therapies. ... Dyno’s technology uses artificial intelligence to design novel capsids, the cell-targeting protein shell of viral vectors.

  • Duchenne UK backs Evox dystrophin delivery project Duchenne UK backs Evox dystrophin delivery project

    The funding round will help Evox carry out preclinical studies on dystrophin-bearing exosomes, to see if the approach can be an alternative to other emerging DMD therapies that try to ... to be used in gene therapies that are based on viral vectors.

  • Spark closes on first US gene therapy approval Spark closes on first US gene therapy approval

    serious side effects seen in some early trials of the approach in the late 1990s and early 2000s, linked to the viral vectors used to deliver the therapies. ... Since then, considerable effort has gone into improving the targeting of viral vectors and

  • Latest NICE drug recommendations

    This guidance means that patients with the virus will have another treatment option available to combat the problem of viral resistance to other drug therapies.".

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Oncolytic viral therapies, including VSV‐GP platform targeting a broad range of cancers. ... The technology will take patient samples and screen them for shared antigen and neoantigen TCRs for use in adoptive cellular therapies.

  • Pharma deals continue to slide Pharma deals continue to slide

    Gilead has been trying to diversify away from anti-viral therapies into oncology and Kite is a good fit with its CAR-T technology and a lead product in priority review

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    Alios / J&J. Company acquisition. Anti-viral therapies, lead compound AL-8176 an oral antiviral in phase II for infant RSV.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To transform lives through communication that changes behaviour and improves health outcomes....

Latest intelligence

Time to talk about health inequalities
Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK...
The speed of science and the pace of comms
Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
Improving cardiovascular disease care and awareness
Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...

Quick links